These findings expand our understanding of the mechanisms by which HuR promotes radiation resistance, and underscore the value of targeting the HuR–ARID1A axis in order to enhance the effectiveness of radiotherapy for patients with breast cancer. Here, ELAVL1 is linked to breast carcinoma.